Systematix revises rating on Pfizer and Jubilant Pharmova to Hold but maintian its price target.
(Photo Source: freepik)
Pfizer and Divi's Laboratories outperformance was driven by better than expected revenue growth and margin expansion while Jubilant Pharmova, Dr. Reddy's and Zydus Lifesciences reported lower operational costs, thus aiding operating profit outperformance.